biostudies-literatureUnknown9Rong X<h4>Aim of the review</h4>To assess the risk of hypovolemia for sodium-glucose cotransporter-2 (SGLT2) inhibitors treatment.<h4>Method</h4>A systematic literature retrieval was performed in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and Scopus from inception up to 4 October 2022, Data for study characteristics and outcomes of interest were extracted from each eligible study. Risk ratios (RRs) with a 95% confidence interval (CI) for hypovolemia were calculated using a random-effect model.<h4>Results</h4>A total of 57 studies (<i>n</i> = 68,622) were included in our meta-analysis, with a result of 1,972 hypovolemia incidents (1,142 in the SGLT2 inhibitors group and 830 in the control group). The pooled RR was 1.12 (95% CI: 1.02-1.22). It is evident that receiving SGLT2 inhibitors increased the risk of hypovolemia. When stratified by category of SGLT2 inhibitors the result was consistent; when the subgroup was analyzed by age, the pooled RR was 1.07 (95% CI: 0.94-1.23) in patients aged ≥65 years and 1.14 (95% CI: 1.02-1.28) in those aged <65 years. When comparing the baseline estimated glomerular filtration rate (eGFR) of less than or equal to 60 mL/min/1.73 m² with a baseline eGFR greater than 60 mL/min/1.73 m², the pooled RR was 1.21, (95% CI: 1.00-1.46) and 1.08, (95%CI: 0.98-1.20), respectively.<h4>Conclusion</h4>Our meta-analysis has demonstrated that SGLT2 inhibitors increased the risk of hypovolemia in patients with Type 2 Diabetes Mellitus (T2DM). It is necessary to pay attention to the risk of hypovolemia associated with SGLT2 inhibitors, especially in older individuals and those with moderate renal impairment.<h4>Systematic review registration</h4>[https://www.crd.york.ac.uk/prospero/], identifier [CRD42020156254].Frontiers in cardiovascular medicine973129https://www.ebi.ac.uk/biostudies/studies/S-EPMC9701837biostudies-literatureRisk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials.PMC9701837Li XGou QRong XLiu KZhu YWen BChen XfalseRisk of hypovolemia associated with sodium-glucose cotransporter-2 inhibitors treatment: A meta-analysis of randomized controlled trials.<h4>Aim of the review</h4>To assess the risk of hypovolemia for sodium-glucose cotransporter-2 (SGLT2) inhibitors treatment.<h4>Method</h4>A systematic literature retrieval was performed in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and Scopus from inception up to 4 October 2022, Data for study characteristics and outcomes of interest were extracted from each eligible study. Risk ratios (RRs) with a 95% confidence interval (CI) for hypovolemia were calculated using a random-effect model.<h4>Results</h4>A total of 57 studies (<i>n</i> = 68,622) were included in our meta-analysis, with a result of 1,972 hypovolemia incidents (1,142 in the SGLT2 inhibitors group and 830 in the control group). The pooled RR was 1.12 (95% CI: 1.02-1.22). It is evident that receiving SGLT2 inhibitors increased the risk of hypovolemia. When stratified by category of SGLT2 inhibitors the result was consistent; when the subgroup was analyzed by age, the pooled RR was 1.07 (95% CI: 0.94-1.23) in patients aged ≥65 years and 1.14 (95% CI: 1.02-1.28) in those aged <65 years. When comparing the baseline estimated glomerular filtration rate (eGFR) of less than or equal to 60 mL/min/1.73 m² with a baseline eGFR greater than 60 mL/min/1.73 m², the pooled RR was 1.21, (95% CI: 1.00-1.46) and 1.08, (95%CI: 0.98-1.20), respectively.<h4>Conclusion</h4>Our meta-analysis has demonstrated that SGLT2 inhibitors increased the risk of hypovolemia in patients with Type 2 Diabetes Mellitus (T2DM). It is necessary to pay attention to the risk of hypovolemia associated with SGLT2 inhibitors, especially in older individuals and those with moderate renal impairment.<h4>Systematic review registration</h4>[https://www.crd.york.ac.uk/prospero/], identifier [CRD42020156254].2022-01-01T00:00:00Z20222026-06-22T03:13:03.674Z2025-04-06T13:06:10.601ZS-EPMC97018373645191910.3389/fcvm.2022.973129